Biosimilar Clinical Development: Scientific Considerations and New Methodologies (Chapman & Hall/CRC Biostatistics) - Softcover

Buch 77�von 151: Chapman & Hall/CRC Biostatistics

9780367736521: Biosimilar Clinical Development: Scientific Considerations and New Methodologies (Chapman & Hall/CRC Biostatistics)

Softcover

ISBN 10: 0367736527 ISBN 13: 9780367736521

Verlag: Routledge, 2020

Alle Exemplare dieser ISBN-Ausgabe

0 Gebraucht

3 Neu

Von EUR 66,32

Biosimilars have the potential to change the way we think about, identify, and manage health problems. They are already impacting both clinical research and patient care, and this impact will only grow as our understanding and technologies improve. Written by a team of experienced specialists in clinical development, this book discusses various potential drug development strategies, the design and analysis of pharmacokinetics (PK) studies, and the design and analysis of efficacy studies.

Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.

�ber die Autorin bzw. den Autor

Dr. Kerry B. Barker is the Vice-President and Head of Early Oncology Research Statistics at Pfizer, Dr. Sandeep Menon is the Vice-President and Head of Biostatistics Research and Consulting Center at Pfizer , Dr. Ralph D’Agostino is a professor of Mathematics and Statistics at Boston University, Dr. Siyan Xu is a senior principal biostatistician at Novartis and Dr.Bo Jin is the Director of Biostatistics in Early Oncology Research at Pfizer. All have been involved with biosimilars clinical development across all regions of the world.

��ber diesen Titel� kann sich auf eine andere Ausgabe dieses Titels beziehen.

Verlag: Routledge
Erscheinungsdatum: 2020
Sprache: Englisch
ISBN 10: 0367736527
ISBN 13: 9780367736521
Einband: Taschenbuch
Anzahl der Seiten: 268
Herausgeber: Barker Kerry B., Menon Sandeep M., D'Agostino Sr., Xu Siyan
Kontakt zum Hersteller: Nicht verf�gbar
Verantwortliche Person: Buchb�r
info@buchbaer.de

Weberstr. 67
Osnabr�ck
49084
Deutschland